lb pharmaceuticals to present at major investor conferences in september
News provided byLB Pharmaceuticals Inc · 1 min read
NEW YORK, Sept. 03, 2026 /CourierPR/ -- LB Pharmaceuticals Inc, a neuromedicines company focused on developing high-impact therapies for underserved brain disorders, will participate in several upcoming investor conferences in September 2026, presenting and engaging with potential investors.
On September 9, members of the company's executive team will meet with investors at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA. These one-on-one meetings will provide an opportunity for in-depth discussions.
From September 14 to 23, LB Pharmaceuticals will also present and participate in the H.C. Wainwright 28th Annual Global Investment Conference and the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The company will deliver a presentation at the H.C. Wainwright conference on Monday, September 14, starting at 10:00 a.m. ET, and will host virtual one-on-one meetings. On Wednesday, September 23, at 2:30 p.m. ET, the company will participate in a virtual fireside chat at the TD Cowen summit.
The presentations and fireside chat will be available for viewing on the "Investors" page under the "Events" section of LB Pharmaceuticals’ website at <https://ir.lbpharma.us/>. A replay of these sessions will be archived for future reference.
LB Pharmaceuticals is committed to advancing its pipeline, particularly its lead product candidate, LB-102, which it believes could be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. If approved, LB-102 could become a cornerstone of psychiatric practice, offering a balanced clinical activity and tolerability profile that could serve as an attractive alternative to both branded and generic therapeutics for a broad range of neuropsychiatric diseases.